Pörssitiedote

Number of Shares and Votes in Nanologica AB (publ)

The number of registered shares and votes in Nanologica AB has changed during the month of October following the registration of parts of the previously communicated rights issue.

The rights issue was subscribed with and without the support of unit rights to approximately 87.0 percent, and has in this part been allotted and registered with the Swedish Companies Registration Office. This means that the number of shares in Nanologica during October has increased by 38,423,596 shares from 44,178,618 to 82,602,214 shares and that the share capital has increased by SEK 3,842,359.6 from SEK 4,417,861.8 to SEK 8,260,221.4.

For the remaining approximately 13.0 percent of the rights issue, the underwriting commitment will be utilized. As a result of the regulations for insider trading, and in accordance with the decision on the rights issue, subscription and allotment of units covered by the underwriting commitment is expected to be completed during week 46. Thereafter, the part of the rights issue connected to the underwriting commitment will be registered with the Swedish Companies Registration Office.

The Extraordinary General Meeting on September 23, 2024, resolved to reduce the share capital by an amount in SEK corresponding to the amount by which the share capital increases through the rights issue (regarding the part where the share capital increase is attributable to a new issue of shares), with relevant adjustments to achieve an appropriate quota value. The company intends to carry out a reduction of the share capital either in connection with, or after, the last partial registration of the rights issue.

As of October 31, 2024, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 82,602,214.

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.